

Federal Office of Public Health FOPH
Public Health Directorate Communicable
Diseases Division
Schwarzenburgstrasse 157
3003 Berne
Switzerland

N/réf : LK/MS

Geneva, February 09, 2021

Geneva Centre for
Emerging Viral Diseases

Division of Infectious
Diseases

Department of Medicine


Laboratory of virology

Division of Laboratory
Medicine

Diagnostic Department


SARS-CoV-2 variants: follow-up of previous updates in Geneva

SARS-CoV-2 testing at HUG




Among the Cobas 6800 RT-PCR positive samples, those with a Ct value ≤ 32 are used for 501Y and 484K mutations screening by specific RT-PCR assays.

501Y and 484K mutation screening by RT-PCR among SARS-CoV-2 positive samples collected in GE and addressed to our laboratory for primary diagnosis



In addition, Sanger sequencing confirmed the presence of the P.1 variant in two samples collected on January 29, 2021. For one of the two patients, we know that she came back from Brazil a few days before.

Most recent whole genome sequencing results performed on SARS-CoV-2 positive samples collected in GE and addressed to our laboratory



Conclusions

We observe a continuous increase in the percentage of B.1.1.7 variant among SARS-CoV-2 positive samples in the Geneva area, currently around 70%.

A cluster related to the B.1.351 variant identified in a school in Geneva end of January 2021, seems to be under control. Currently, we do not observe an increase in B.1.351 variant detection.

No new P.2 variant-positive sample has been detected since the previous report.

Two samples from January 29, 2021, were positive for the P.1 variant.

Laurent Kaiser

Samuel Cordey

Manuel Schibler